Top Page
Neurotech International
(Sydney:NTI)
Neurotech International (NTI) vs. iShares MSCI Australia ETF (EWA)
Neurotech International Business Overview & Revenue Model
Neurotech International Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.33M | 2.44M | 1.96K | 5.96K | 38.26K | 206.14K |
| Gross Profit | 8.02M | 2.44M | -5.87K | 4.21K | -535.21K | -238.72K |
| EBITDA | -8.72M | -10.74M | -8.24M | -8.98M | -3.36M | -7.43M |
| Net Income | -3.85M | -10.60M | -5.07M | -7.79M | -3.36M | -7.43M |
Balance Sheet | ||||||
| Total Assets | 6.81M | 3.24M | 12.21M | 5.31M | 2.02M | 5.01M |
| Cash, Cash Equivalents and Short-Term Investments | 6.34M | 3.03M | 11.63M | 5.03M | 1.90M | 4.83M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 932.85K | 285.74K | 314.70K | 1.35M | 592.98K | 1.14M |
| Stockholders Equity | 5.88M | 2.95M | 11.90M | 3.96M | 1.43M | 3.86M |
Cash Flow | ||||||
| Free Cash Flow | -2.97M | -9.02M | -4.60M | -6.32M | -2.96M | -2.32M |
| Operating Cash Flow | -2.97M | -9.02M | -4.60M | -6.32M | -2.96M | -2.32M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -3.21K | 0.00 |
| Financing Cash Flow | 3.35M | 429.53K | 11.19M | 9.45M | 26.40K | 7.13M |
Neurotech International Technical Analysis
Neurotech International Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$24.31M | -2.88 | -103.74% | ― | 14.84% | 39.64% | |
48 Neutral | AU$33.22M | -7.32 | -58.27% | ― | -7.20% | 28.70% | |
43 Neutral | AU$16.85M | -3.51 | -142.71% | ― | -87.88% | -83.93% | |
42 Neutral | AU$15.47M | -0.69 | -385.20% | ― | 126.62% | 33.53% | |
37 Underperform | AU$13.97M | -0.99 | -1476.79% | ― | -2.82% | 32.47% |
Neurotech International Corporate Events
Neurotech International has called a general meeting of shareholders to be held as a physical gathering at BDO Australia’s Melbourne offices on 12 March 2026 at 11:00 a.m. AEDT. In line with recent Corporations Act changes, the company will provide the notice of meeting electronically via the ASX platform, only issuing hard copies on request, and has set 10 March 2026 as the record date for voting eligibility.
Shareholders who cannot attend in person are encouraged to vote by proxy no later than 48 hours before the meeting and may submit questions to the company secretary in advance. The board has signalled that any changes to meeting arrangements will be communicated through ASX announcements and the company’s website, underscoring a continued shift toward digital communication and procedural transparency for investors.
The most recent analyst rating on (AU:NTI) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Neurotech International stock, see the AU:NTI Stock Forecast page.
Neurotech International has secured Human Research Ethics Committee approval to begin its Beyond Harmony Phase 3 clinical study of NTI164 in individuals with autism spectrum disorder Levels 2 and 3, a pivotal step in its strategy to commercialise the cannabinoid-based therapy for paediatric neurological conditions. The trial, designed using robust data from earlier ASD studies showing clinically meaningful symptom and quality-of-life improvements, aims to generate registration-ready evidence for regulators in Australia and the United States, strengthening Neurotech’s pathway toward market authorisation, expanding its clinical footprint in both regions, and potentially enhancing its positioning in the emerging neurodevelopmental therapeutics market.
The most recent analyst rating on (AU:NTI) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Neurotech International stock, see the AU:NTI Stock Forecast page.
Neurotech International reported a pivotal quarter marked by the US FDA granting Rare Pediatric Disease Designation to its lead drug NTI164 for Rett syndrome, adding to existing US and European Orphan Drug Designations and significantly enhancing the program’s regulatory, commercial and partnering appeal through potential access to priority review, tax incentives and extended market exclusivity. Supporting its broader paediatric neurology strategy, new clinical and mechanistic data from an open-label Phase I/II trial of NTI164 in children with PANS were published in the high-impact journal Neurotherapeutics, showing the therapy was well tolerated and delivered statistically significant improvements across key disease domains while normalising dysregulated epigenetic, ribosomal and immune pathways, thereby strengthening the scientific rationale for NTI164 across multiple neuroinflammatory paediatric indications. Financially, Neurotech bolstered its balance sheet with approximately $4 million raised via a placement backed by both new and existing investors, alongside a $4.73 million R&D tax incentive refund, funding IND-enabling toxicology, registration-focused clinical development and regulatory activities as the company advances NTI164 toward later-stage trials and positions itself for future regulatory engagement and potential partnering discussions.
The most recent analyst rating on (AU:NTI) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Neurotech International stock, see the AU:NTI Stock Forecast page.
Neurotech International has reported that clinical and mechanistic data for its proprietary medicinal cannabis‑derived drug NTI164 in paediatric acute‑onset neuropsychiatric syndrome (PANS) have been published in Neurotherapeutics, a high‑impact peer‑reviewed journal, reinforcing the scientific credibility of its development pipeline. In a 12‑week Phase I/II open‑label study of 14 children with chronic, relapsing PANS, NTI164 was well tolerated and delivered statistically significant improvements across key disease domains including overall disease severity, anxiety, obsessive‑compulsive symptoms, tics, ADHD symptoms and quality of life. Multi‑omics analyses showed that PANS is associated with widespread dysregulation of epigenetic, ribosomal and immune pathways, which were significantly normalised following NTI164 treatment, providing molecular evidence that the drug modulates core disease mechanisms. Publication of both the clinical outcomes and mechanistic data in a leading journal is being positioned by management as an important validation step that strengthens NTI164’s scientific foundation and underpins its continued development for PANS and other paediatric neuroinflammatory indications, potentially enhancing Neurotech’s standing among clinicians, regulators and investors in the paediatric neurology space.
The most recent analyst rating on (AU:NTI) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Neurotech International stock, see the AU:NTI Stock Forecast page.
Neurotech International has issued new ordinary fully paid shares without a prospectus under the Corporations Act, confirming that it remains compliant with its financial reporting and continuous disclosure obligations and that there is no excluded information that would reasonably be expected in a formal disclosure document. The board-authorised move signals routine capital management by the clinical-stage paediatric neurology specialist, with the company emphasising regulatory compliance as it advances development of its NTI164 cannabinoid therapy across multiple neurological indications.
Neurotech International has applied to the ASX for quotation of 246.7 million new ordinary fully paid shares, expanding its listed securities on the Australian market. The issuance, lodged via an Appendix 2A application and tied to previously flagged transactions, significantly increases the company’s share count and is likely to affect its capital structure and liquidity profile for existing and prospective shareholders.
Neurotech International has disclosed a change in director Gerald Quigley’s interests, confirming the lapse of 5,000,000 unlisted options (NTIOPT20, exercisable at $0.10 and expiring 23 December 2025), which were held directly. Following this lapse, Quigley’s remaining interest is an indirect holding of 277,777 fully paid ordinary shares via a nominee and custodial structure, with no cash consideration involved and no trades occurring during a closed period, indicating a reduction in his potential equity exposure while leaving his existing shareholding intact.
Neurotech International Limited has allowed 5 million unlisted options, exercisable at $0.10 and due to expire on 23 December 2025, to lapse without being exercised. The expiry of these options reduces the company’s pool of potential future equity issuance, slightly simplifying its capital structure but having no immediate impact on the number of ordinary shares on issue or existing shareholders’ current holdings.
Neurotech International has secured binding commitments for a $4 million placement from both existing and new investors, with directors also participating. The funds will be used to advance NTI164’s non-clinical toxicology and clinical programs, regulatory submissions, and general working capital, strengthening the company’s position in developing treatments for paediatric neurological disorders.
Neurotech International Limited has requested a trading halt on its securities pending an announcement related to a capital raising initiative. This move indicates a strategic step by the company to potentially enhance its financial resources, which could impact its market positioning and stakeholder interests.
Neurotech International Limited held its Annual General Meeting, where all resolutions were determined by a poll. The meeting’s outcomes, including the adoption of the remuneration report and re-election of Mark Davies, were carried successfully, indicating strong shareholder support. This meeting underscores Neurotech’s stable governance and continued focus on advancing its clinical programs, potentially enhancing its position in the biopharmaceutical industry.